Compare Becton Dickinson and Co (BDX) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs F5 Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while F5 Inc trades at $433.94 (market cap $24.33B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and Becton Dickinson and Co pays a 2.79% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| BDX | FFIV | |
|---|---|---|
Market Cap | $41.51B | $24.33B |
Sector | Health | Technology |
52-Week High | $185.39 | $431.26 |
52-Week Low | $135.49 | $223.99 |
Enterprise Value | $57.97B | $23.15B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
F5 Networks (FFIV) trades at $420.95, down 2.19% today, with a bullish technical signal from moving averages and strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $3.90 exceeding the $3.46 estimate. Revenue growth accelerated to $3.09 billion in 2025, while net income margins expanded to 22.42%. Recent strategic moves include expanding AI security capabilities through the SurePath AI acquisition and new executive appointments.
FFIV presents a mixed outlook with strong operational execution offset by premium valuations. The stock trades above analyst consensus target of $397, though institutional sentiment remains positive with 40% buy ratings. Key risks include competitive pressures in cybersecurity and execution challenges in AI integration. Earnings growth and margin expansion remain the primary catalysts for further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
